Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to compare the concordance between chest computerized tomography-scan (CTscan) and Magnetic resonance Imaging (MRI) for the description of the abnormalities seen in Allergic BronchoPulmonary Aspergillosis (ABPA).


Clinical Trial Description

The ABPA is responsible for pulmonary exacerbations in chronic bronchial diseases. The treatment of ABPA consists in systemic corticosteroids and anti fungal therapy, which can have severe side effects. The diagnosis is difficult, based on several but non-specific characteristics. One of the radiologic abnormalities on CTscan could be more specific : high attenuation in impacted mucus, but this sign is found in about 30% of cases. Recent articles and investigators experience seem to demonstrate that MRI could provide an interesting tool for ABPA diagnosis, studying the signal of bronchial impactions. The aim of the study is to describe the MRI characteristics of patients with ABPA and compare the results with those obtained by CTscan, and in order to determine if there is a specific signal of impaction in ABPA. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03265366
Study type Interventional
Source University Hospital, Bordeaux
Contact
Status Completed
Phase N/A
Start date September 14, 2017
Completion date January 24, 2020

See also
  Status Clinical Trial Phase
Completed NCT03133299 - A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma Phase 2/Phase 3